Taiwan Changes Plans For Biotech Park
This article was originally published in PharmAsia News
Executive SummaryTaiwan authorities have altered plans to add a major facility as part of the National Biotechnology Development Park as the center of its program to build a domestic biotechnology industry
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.